Literature DB >> 8806235

Synergistic interaction of photodynamic treatment with the sensitizer aluminum phthalocyanine and hyperthermia on loss of clonogenicity of CHO cells.

M H Rasch1, K Tijssen, J VanSteveninck, T M Dubbelman.   

Abstract

When CHO cells were exposed to hyperthermia and subsequently to photodynamic treatment, the combined effects were additive but in the reverse sequence the interaction was synergistic. The synergistic interaction comprised two quite different components: (1) photodynamically induced sensitization of cellular proteins and/or supramolecular structures for thermal inactivation and (2) a photodynamically induced inhibition of the cellular repair system for sublethal thermal damage. The first component of the synergistic interaction was reflected by a change of the Arrhenius parameters of thermal cell killing. A lowering of the activation energy of this process was responsible for the synergistic interactions, whereas a concomitant decrease of the frequency factor, opposing this effect, actually caused a much lower degree of synergism at higher temperatures. This component of the synergistic interaction did not respond to the insertion of an intermediate incubation period between the two treatments. The second component of the synergistic interaction, viz the interference with the ability of cells to survive sublethal thermal damage, was reversible, as an intermediate incubation between photodynamic treatment and hyperthermia resulted in its repair. The photodynamically induced inhibition of the ability of cells to survive sublethal thermal damage was not related to ATP or glutathione depletion, inhibition of de novo protein synthesis or impairment of degradation of damaged protein molecules. Restoration of the repair system for sublethal damage depended on a metabolic process and required free intracellular Ca2+, suggesting that a cell signaling pathway may be involved. Thus, in a practical sense the magnitude of the synergistic interaction between photodynamic treatment and hyperthermia depends on the length of the interval between the two treatments and on the temperature and duration of the subsequent thermal treatment. This may have significant consequences for the development of clinical protocols for the combined application of photodynamic therapy and hyperthermia in the treatment of tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806235     DOI: 10.1111/j.1751-1097.1996.tb03109.x

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  6 in total

1.  Enhanced cytotoxic effects of 5-aminolevulinic acid-mediated photodynamic therapy by concurrent hyperthermia in glioma spheroids.

Authors:  Henry Hirschberg; Chung-Ho Sun; Bruce J Tromberg; Alvin T Yeh; Steen J Madsen
Journal:  J Neurooncol       Date:  2004-12       Impact factor: 4.130

Review 2.  Photodynamic therapy.

Authors:  T J Dougherty; C J Gomer; B W Henderson; G Jori; D Kessel; M Korbelik; J Moan; Q Peng
Journal:  J Natl Cancer Inst       Date:  1998-06-17       Impact factor: 13.506

3.  Combined concurrent photodynamic and gold nanoshell loaded macrophage-mediated photothermal therapies: an in vitro study on squamous cell head and neck carcinoma.

Authors:  Anthony J Trinidad; Seok Jin Hong; Qian Peng; Steen J Madsen; Henry Hirschberg
Journal:  Lasers Surg Med       Date:  2014-03-20       Impact factor: 4.025

4.  Water-soluble aluminium phthalocyanine-polymer conjugates for PDT: photodynamic activities and pharmacokinetics in tumour-bearing mice.

Authors:  N Brasseur; R Ouellet; C La Madeleine; J E van Lier
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

5.  Combined hyperthermia and chlorophyll-based photodynamic therapy: tumour growth and metabolic microenvironment.

Authors:  D K Kelleher; O Thews; A Scherz; Y Salomon; P Vaupel
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

6.  Enhanced effects of aminolaevulinic acid-based photodynamic therapy through local hyperthermia in rat tumours.

Authors:  D K Kelleher; J Bastian; O Thews; P Vaupel
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.